A detailed history of Gibbs Wealth Management transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Gibbs Wealth Management holds 4,674 shares of GILD stock, worth $579,996. This represents 0.12% of its overall portfolio holdings.

Number of Shares
4,674
Previous 5,398 13.41%
Holding current value
$579,996
Previous $598 Million 13.31%
% of portfolio
0.12%
Previous 0.12%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 30, 2025

SELL
$108.22 - $120.47 $78,351 - $87,220
-724 Reduced 13.41%
4,674 $519 Million
Q2 2025

Aug 13, 2025

BUY
$96.91 - $113.0 $523,120 - $609,974
5,398 New
5,398 $598 Million
Q1 2025

Nov 04, 2025

BUY
$89.14 - $117.41 $43,678 - $57,530
490 Added 12.4%
4,441 $498 Million
Q4 2024

Nov 04, 2025

BUY
$83.95 - $97.9 $13,599 - $15,859
162 Added 4.28%
3,951 $365 Million
Q3 2024

Nov 04, 2025

SELL
$66.59 - $83.99 $58,932 - $74,331
-885 Reduced 18.93%
3,789 $318 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $156B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Gibbs Wealth Management Portfolio

Follow Gibbs Wealth Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gibbs Wealth Management, based on Form 13F filings with the SEC.

News

Stay updated on Gibbs Wealth Management with notifications on news.